{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:31Z","timestamp":1787027011082,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    The use of glucagon-like peptide-1 (GLP-1) receptor agonists by young populations is rapidly increasing worldwide, thereby exposing more women of childbearing age. Dulaglutide, a long-acting GLP-1 receptor agonist designed to bind to the neonatal Fc receptor (FcRn) and approved for type 2 diabetes mellitus, reflects this trend. In this study, we wanted to evaluate transplacental passage of dulaglutide and its potential effects on placental function. Transplacental transfer was investigated both with human placenta perfusions, a model for term transfer and expressing FcRn; and with permeability assays across BeWo b30 cell layers, a model for the early pregnancy placental barrier and characterised by negligible FcRn expression. Additional\n                    <jats:italic>in vitro<\/jats:italic>\n                    experiments were performed with human placental explants and BeWo cells. Placenta perfusions revealed minimal but consistent transplacental passage of dulaglutide (0.2%\u20130.7%; at 1.9\u00a0nM and 19.1\u00a0nM, over 4\u00a0hours); fluorescently labelled dulaglutide was detected within foetal villi of perfused tissue, with co-localisation to the early endosome marker Rab5. Permeability assays revealed negligible transfer. Dulaglutide exposure did not impair viability, alter the secretion of pregnancy-related hormones, nor affect glycolytic metabolism neither in human placental explants nor in BeWo cells. Our results suggest that dulaglutide has no adverse effects on placental viability and functions and is not able to cross the placental barrier at earlier gestation stages. However, its ability to cross the placental barrier at term in minimal amounts, but consistently, indicates foetal exposure during late pregnancy, when FcRn is expressed.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1765815","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:32:37Z","timestamp":1768285957000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models"],"prefix":"10.3389","volume":"16","author":[{"given":"Sabrina","family":"Kuoni","sequence":"first","affiliation":[{"name":"Department of Obstetrics, University Hospital Zurich","place":["Zurich, Switzerland"]},{"name":"University of Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Caviglia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, University Hospital Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dolder","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, University Hospital Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gawinecka","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ochsenbein-K\u00f6lble","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, University Hospital Zurich","place":["Zurich, Switzerland"]},{"name":"University of Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Sim\u00f5es-W\u00fcst","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, University Hospital Zurich","place":["Zurich, Switzerland"]},{"name":"University of Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1001\/jama.2019.4981","article-title":"Management of preexisting diabetes in pregnancy: a review","volume":"321","author":"Alexopoulos","year":"2019","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2337\/dc22-S015","article-title":"Management of diabetes in pregnancy: standards of medical care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1385\/1-59259-989-3:225","article-title":"In vitro models for studying trophoblast transcellular transport","volume":"122","author":"Bode","year":"2006","journal-title":"Methods Mol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology Information services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"160403","DOI":"10.1016\/j.scitotenv.2022.160403","article-title":"Experimental human placental models for studying uptake, transport and toxicity of micro- and nanoplastics","volume":"860","author":"Dusza","year":"2023","journal-title":"Sci. Total Environ."},{"key":"B6","article-title":"Product information - trulicity (dulaglutide)","year":"2014"},{"key":"B7","article-title":"Drug approval package, trulicity (dulaglutide) injection","year":"2014"},{"key":"B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2023.07.029","article-title":"Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation","volume":"361","author":"Fein","year":"2023","journal-title":"J. Control Release"},{"key":"B9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/intimm\/13.8.993","article-title":"The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans","volume":"13","author":"Firan","year":"2001","journal-title":"Int. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/plac.1999.0494","article-title":"Production of interleukin (IL)-6 and IL-8 by a choriocarcinoma cell line, BeWo","volume":"21","author":"Fujisawa","year":"2000","journal-title":"Placenta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1933719118812739","article-title":"The impact of immunosuppressive drugs on human placental explants","volume":"26","author":"Gomes","year":"2019","journal-title":"Reprod. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"50401","DOI":"10.3791\/50401","article-title":"Determination of the transport rate of xenobiotics and nanomaterials across the placenta using the ex vivo human placental perfusion model","author":"Grafm\u00fcller","year":"2013","journal-title":"J. Vis. Exp."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1111\/cts.70049","article-title":"On placental and lactational transfer of IgG-based therapeutic proteins - current understanding and knowledge gaps from a clinical pharmacology perspective","volume":"17","author":"Guinn","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/biomedicines11010143","article-title":"The molecular pharmacology of phloretin: anti-inflammatory mechanisms of action","volume":"11","author":"Habtemariam","year":"2023","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.crtox.2022.100081","article-title":"The effect of ethanol and nicotine on ER stress in human placental villous explants","volume":"3","author":"Huovinen","year":"2022","journal-title":"Curr. Res. Toxicol."},{"key":"B18","volume-title":"IDF diabetes atlas","year":"2021"},{"key":"B19","article-title":"Pr\u00e4konzeptionsberatung \u2013 preconception care","volume-title":"Expertenbrief no 92 (ersetzt no. 33)","author":"Krischer","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","first-page":"116177","DOI":"10.1016\/j.biopha.2024.116177","article-title":"Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: an ex vivo human placenta perfusion and in vitro study","volume":"171","author":"Kuoni","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like Peptide-1 receptor agonists to adolescents and young adults, 2020-2023","volume":"331","author":"Lee","year":"2024","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12972","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/0002-9378(95)90336-4","article-title":"Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta","volume":"173","author":"Malek","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1600-0897.1997.tb00513.x","article-title":"Protein transport across the in vitro perfused human placenta","volume":"38","author":"Malek","year":"1997","journal-title":"Am. J. Reprod. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/a:1016674503298","article-title":"Capacity for hormone production of cultured trophoblast cells obtained from placentae at term and in early pregnancy","volume":"18","author":"Malek","year":"2001","journal-title":"J. Assist. Reprod. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.placenta.2004.10.002","article-title":"Human placental explants in culture: approaches and assessments","volume":"26","author":"Miller","year":"2005","journal-title":"Placenta"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"985646","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","article-title":"Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer","volume":"116","author":"Porter","year":"2016","journal-title":"J. Reprod. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1193271","DOI":"10.3389\/fendo.2023.1193271","article-title":"Management of type 2 diabetes in pregnancy: a narrative review","volume":"14","author":"Raets","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1038\/s41598-017-06364-z","article-title":"A comparative study of five physiological key parameters between four different human trophoblast-derived cell lines","volume":"7","author":"Rothbauer","year":"2017","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.placenta.2022.07.019","article-title":"Contribution of the ex vivo placental perfusion model in understanding transplacental immunoglobulin G transfer","volume":"127","author":"Sand","year":"2022","journal-title":"Placenta"},{"key":"B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14712598.2017.1296131","article-title":"Dulaglutide for the treatment of type 2 diabetes","volume":"17","author":"Scheen","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/s0264-410x(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/eji.1830260718","article-title":"An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta","volume":"26","author":"Simister","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","article-title":"Drug transfer and metabolism by the human placenta","volume":"43","author":"Syme","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/dom.12660","article-title":"Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment","volume":"18","author":"Umpierrez","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107004","DOI":"10.1289\/ehp4860","article-title":"Transfer and metabolism of the xenoestrogen zearalenone in human perfused placenta","volume":"127","author":"Warth","year":"2019","journal-title":"Environ. Health Perspect."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1765815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:57:45Z","timestamp":1768899465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1765815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1765815"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1765815","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1765815"}}